Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667217 | 0.92 | LMNA (0.65) | LMNAL3MBTL1PPARGRXRAPTGES | |
| SCHEMBL13693266 | 0.88 | RXRA (0.60) | LMNAL3MBTL1PPARGRXRAALOX5 | |
| SCHEMBL15358891 | 0.88 | HDAC1 (0.52) | LMNAPPARGPTGESALOX5HDAC1 | |
| SCHEMBL11315400 | 0.87 | PPARA (0.53) | PPARGRXRAPTGESALOX5THRA | |
| SCHEMBL11309367 | 0.87 | PPARA (0.53) | PPARGRXRAPTGESALOX5THRA | |
| SCHEMBL15255728 | 0.87 | HDAC1 (0.51) | LMNAL3MBTL1PPARGPTGESALOX5 | |
| SCHEMBL2840795 | 0.86 | FFAR4 (0.55) | LMNAL3MBTL1HDAC1HDAC2FFAR4 | |
| SCHEMBL15255731 | 0.85 | HDAC1 (0.50) | LMNAL3MBTL1PPARGPTGESALOX5 | |
| SCHEMBL3693650 | 0.85 | LMNA (0.60) | LMNAL3MBTL1HDAC1HDAC2FFAR4 | |
| SCHEMBL1270107 | 0.85 | HDAC1 (0.53) | LMNAL3MBTL1PPARGRXRAHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2639215-B1 | PREPARATION METHOD FOR SALTS OF KUKOAMINE B | THE FIRST AFFILIATED HOSPITAL THIRD MILITARY MEDICAL UNIVERSTY PLA (CN) | 2017-10-11 | — | — | EP | disclosed |
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ORMCO CORPORATION | 2017-08-03 | — | — | US | disclosed |
| WO-2017132484-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | ACatechol, Inc. (US) | 2017-08-03 | — | — | WO | disclosed |
| US-9365504-B2 | Salts of kukoamine B, preparation method and use thereof | THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY UNIVERSITY, PLA (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20130289112-A1 | SALTS OF KUKOAMINE B, PREPARATION METHOD AND USE THEREOF | TIANJIN CHASESUN PHARMACEUTICAL CO., LTD (CN) | 2013-10-31 | — | — | US | disclosed |
| EP-2639215-A1 | SALTS OF KUKOAMINE B, PREPARATION METHOD AND USE THEREOF | The First Affiliated Hospital, Third Military Medical Universty, PLA (CN) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013072071-A1 | MULTIMODAL CONTRAST AND RADIOPHARMACEUTICAL AGENT FOR AN IMAGING AND A TARGETED THERAPY GUIDED BY IMAGING | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-05-23 | — | — | WO | disclosed |
| US-7812038-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | BIEDIGER RONALD J | 2006-12-07 | — | — | US | disclosed |
| US-6972296-B2 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276476-A1 | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors | VCAM1, ICAM1, ITGA1 | LMNA 1820/4885L3MBTL1 3947/4885PPARG 542/4885 |
| US-20170217997-A1 | PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE | SP1, GPER1, ESR1 | LMNA 935/4885L3MBTL1 4083/4885PPARG 729/4885 |
| US-20130289112-A1 | SALTS OF KUKOAMINE B, PREPARATION METHOD AND USE THEREOF | TLR4, BDKRB1, KLKB1 | LMNA 2099/4885L3MBTL1 2984/4885PPARG 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.